Sign Out
Hypersensitivity to ticagrelor or any of the excipients (see Adverse Reactions).
Active pathological bleeding.
History of intracranial haemorrhage (see Adverse Reactions).
Severe hepatic impairment (see Dosage & Administration, Precautions and Pharmacology: Pharmacokinetics under Actions).
Co-administration of ticagrelor with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir) is contraindicated, as co-administration may lead to a substantial increase in exposure to ticagrelor (see Precautions and Interactions).
